Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-24T02:59:19.288Z Has data issue: false hasContentIssue false
  • English
  • Français

Homeostasis Model Assessment of IR (HOMA-IR) and Metabolic Syndrome (MetS) in First Episode Psychosis

Published online by Cambridge University Press:  01 September 2022

E. Garcia De Jalon ,
L. Aranguren Conde ,
A. Aquerreta Unzue ,
G. Gutiérrez Talavera  and
A. Corrales Rodriguez
E. Garcia De Jalon
Affiliation:
SERVICIO NAVARRO DE SALUD, Programa De Primeros Episodios, PAMPLONA, Spain
L. Aranguren Conde*
Affiliation:
SERVICIO NAVARRO DE SALUD, Programa De Primeros Episodios, PAMPLONA, Spain
A. Aquerreta Unzue
Affiliation:
SERVICIO NAVARRO DE SALUD, Programa De Primeros Episodios, PAMPLONA, Spain
G. Gutiérrez Talavera
Affiliation:
Complejo Hospitalario de Navarra, Psiquiatría, Pamplona, Spain
A. Corrales Rodriguez
Affiliation:
SERVICIO NAVARRO DE SALUD, Psiquiatría. Complejo Hospitalario De Navarra, PAMPLONA, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Metabolic syndrome (MetS) is common in chronic psychosis but also exists in the early stages. HOMA-IR is an independent predictor of cardiovascular diseases and has already been described in first episode of psychosis.

Objectives

To determine whether HOMA levels differ according to MetS at each time assessment over 2 years.

Methods

MetS and HOMA levels are determined at baseline and at 6, 12, 18 and 24 months in a sample of 50 patients participating in the PEPsNa Early Intervention Programme during two years of follow-up. Adult Treatment Panel III (ATP III) criteria are used to define MetS. Insulin resistance measured with the Homeostatic Model Assessment (HOMA-IR) is computed with the formula fasting plasma glucose (mg/dL) times fasting insulin (mIU/mL) divided by 405. Mann-Whitney U Test are used to compare HOMA variable according to presence of metabolic syndrome.

Results

The results showed that HOMA levels differed statistically significantly between patients who met MetS criteria and those who did not at 12 (p<0.046) and 24 (p<0.004) months of treatment.

Conclusions

Given the small sample size the results of our study indicate that there is a sustained relationship over time between HOMA levels and Metabolic Syndrome (MetS) and that the HOMA IR may be useful in identifying those patients with an increased metabolic and cardiovascular risk.

Disclosure

No significant relationships.

Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S769
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.